| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Hematopoietic Stem Cell Transplantation | 30 | 2019 | 2426 | 2.64 | Why? |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 10 | 2019 | 526 | 2.17 | Why? |
| Graft vs Host Disease | 13 | 2019 | 501 | 2.10 | Why? |
| Leukemia | 7 | 2019 | 598 | 2.00 | Why? |
| Leukemia, Myelomonocytic, Juvenile | 8 | 2018 | 27 | 1.82 | Why? |
| Killer Cells, Natural | 12 | 2020 | 2093 | 1.49 | Why? |
| Myelodysplastic Syndromes | 4 | 2018 | 261 | 1.42 | Why? |
| Receptors, Antigen, T-Cell, alpha-beta | 3 | 2018 | 203 | 1.31 | Why? |
| Lymphocyte Depletion | 3 | 2018 | 293 | 1.28 | Why? |
| Antineoplastic Combined Chemotherapy Protocols | 10 | 2019 | 1573 | 1.21 | Why? |
| Leukemia, Myeloid, Acute | 8 | 2018 | 676 | 1.14 | Why? |
| T-Lymphocytes | 11 | 2020 | 6670 | 1.06 | Why? |
| Azacitidine | 3 | 2018 | 42 | 1.04 | Why? |
| HLA Antigens | 6 | 2020 | 830 | 0.94 | Why? |
| Protein Tyrosine Phosphatase, Non-Receptor Type 11 | 2 | 2018 | 14 | 0.92 | Why? |
| Leukemia, Promyelocytic, Acute | 3 | 2018 | 60 | 0.91 | Why? |
| Unrelated Donors | 2 | 2018 | 187 | 0.89 | Why? |
| Hodgkin Disease | 3 | 2018 | 204 | 0.87 | Why? |
| Transplantation, Homologous | 9 | 2019 | 757 | 0.87 | Why? |
| Proto-Oncogene Proteins p21(ras) | 2 | 2018 | 100 | 0.86 | Why? |
| Antilymphocyte Serum | 2 | 2017 | 80 | 0.84 | Why? |
| Cord Blood Stem Cell Transplantation | 5 | 2018 | 143 | 0.81 | Why? |
| Antibodies, Bispecific | 2 | 2018 | 207 | 0.79 | Why? |
| Haplotypes | 2 | 2020 | 853 | 0.78 | Why? |
| Graft vs Leukemia Effect | 1 | 2018 | 3 | 0.77 | Why? |
| Lymphoma, Large-Cell, Anaplastic | 1 | 2018 | 24 | 0.76 | Why? |
| Child, Preschool | 53 | 2020 | 36283 | 0.73 | Why? |
| Immunoconjugates | 1 | 2018 | 90 | 0.72 | Why? |
| Translocation, Genetic | 4 | 2018 | 40 | 0.72 | Why? |
| Proto-Oncogene Proteins c-myc | 4 | 2018 | 43 | 0.72 | Why? |
| GTP Phosphohydrolases | 1 | 2018 | 89 | 0.70 | Why? |
| Neuroblastoma | 5 | 2018 | 91 | 0.69 | Why? |
| Child | 68 | 2020 | 70012 | 0.65 | Why? |
| Infant | 44 | 2020 | 30274 | 0.63 | Why? |
| Bortezomib | 1 | 2017 | 125 | 0.63 | Why? |
| Chemoradiotherapy | 2 | 2018 | 362 | 0.62 | Why? |
| B-Lymphocytes | 7 | 2020 | 4418 | 0.62 | Why? |
| Transplantation Conditioning | 4 | 2018 | 323 | 0.61 | Why? |
| Thalassemia | 1 | 2018 | 144 | 0.59 | Why? |
| Disease-Free Survival | 13 | 2019 | 1654 | 0.56 | Why? |
| Repressor Proteins | 5 | 2018 | 232 | 0.54 | Why? |
| Neoplasm, Residual | 5 | 2018 | 147 | 0.53 | Why? |
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 3 | 2018 | 82 | 0.50 | Why? |
| Antineoplastic Agents | 7 | 2018 | 3550 | 0.49 | Why? |
| Lymphohistiocytosis, Hemophagocytic | 2 | 2018 | 800 | 0.49 | Why? |
| Allografts | 5 | 2018 | 761 | 0.48 | Why? |
| Graft Rejection | 3 | 2019 | 1766 | 0.46 | Why? |
| Brain Neoplasms | 4 | 2020 | 669 | 0.45 | Why? |
| Alleles | 4 | 2020 | 1557 | 0.43 | Why? |
| Genetic Predisposition to Disease | 5 | 2020 | 4027 | 0.43 | Why? |
| Immune System | 2 | 2020 | 1479 | 0.42 | Why? |
| Antibodies | 1 | 2017 | 846 | 0.42 | Why? |
| Interferon-gamma | 3 | 2020 | 2711 | 0.42 | Why? |
| Adolescent | 44 | 2020 | 86841 | 0.41 | Why? |
| Immunity | 2 | 2021 | 2651 | 0.41 | Why? |
| Recurrence | 10 | 2018 | 3675 | 0.40 | Why? |
| Adaptive Immunity | 2 | 2020 | 2585 | 0.38 | Why? |
| Leukemia, Megakaryoblastic, Acute | 2 | 2019 | 2 | 0.38 | Why? |
| MicroRNAs | 7 | 2018 | 1787 | 0.38 | Why? |
| Tretinoin | 3 | 2018 | 99 | 0.38 | Why? |
| Lymphoproliferative Disorders | 3 | 2017 | 110 | 0.37 | Why? |
| Immunoglobulin A | 1 | 2020 | 3567 | 0.37 | Why? |
| Biomarkers, Tumor | 5 | 2018 | 1314 | 0.37 | Why? |
| RUNX1 Translocation Partner 1 Protein | 2 | 2018 | 2 | 0.37 | Why? |
| Tissue Donors | 4 | 2019 | 1679 | 0.37 | Why? |
| Busulfan | 2 | 2018 | 22 | 0.37 | Why? |
| Cerebellar Neoplasms | 2 | 2018 | 12 | 0.36 | Why? |
| Zinc Finger Protein GLI1 | 2 | 2018 | 5 | 0.36 | Why? |
| Medulloblastoma | 2 | 2018 | 15 | 0.36 | Why? |
| RNA Editing | 2 | 2019 | 80 | 0.36 | Why? |
| Vincristine | 2 | 2017 | 89 | 0.34 | Why? |
| Antineoplastic Agents, Alkylating | 2 | 2017 | 71 | 0.34 | Why? |
| Immunologic Deficiency Syndromes | 3 | 2019 | 368 | 0.34 | Why? |
| Membrane Proteins | 1 | 2018 | 1733 | 0.33 | Why? |
| Apoptosis Regulatory Proteins | 2 | 2018 | 202 | 0.33 | Why? |
| Disease Susceptibility | 1 | 2020 | 4002 | 0.32 | Why? |
| Virus Shedding | 2 | 2020 | 5834 | 0.32 | Why? |
| Remission Induction | 4 | 2018 | 950 | 0.32 | Why? |
| Feces | 1 | 2020 | 4235 | 0.31 | Why? |
| Dexamethasone | 4 | 2019 | 2055 | 0.31 | Why? |
| Glioblastoma | 2 | 2019 | 187 | 0.30 | Why? |
| Gene Expression Regulation, Neoplastic | 5 | 2018 | 1014 | 0.29 | Why? |
| Mutation | 6 | 2018 | 12376 | 0.29 | Why? |
| B7-H1 Antigen | 3 | 2017 | 541 | 0.29 | Why? |
| Cell Differentiation | 7 | 2018 | 1338 | 0.29 | Why? |
| Histocompatibility Testing | 3 | 2018 | 219 | 0.29 | Why? |
| Adaptor Proteins, Signal Transducing | 2 | 2019 | 502 | 0.29 | Why? |
| Doxorubicin | 2 | 2017 | 313 | 0.28 | Why? |
| Hematopoietic Stem Cells | 2 | 2014 | 321 | 0.28 | Why? |
| Glioma | 2 | 2017 | 189 | 0.28 | Why? |
| Female | 69 | 2021 | 380317 | 0.28 | Why? |
| Immunologic Memory | 4 | 2021 | 3362 | 0.28 | Why? |
| Male | 67 | 2021 | 367725 | 0.28 | Why? |
| Bone Marrow Diseases | 2 | 2017 | 27 | 0.28 | Why? |
| Cell Line, Tumor | 12 | 2019 | 3608 | 0.28 | Why? |
| Humans | 114 | 2021 | 930598 | 0.27 | Why? |
| Leukemia, Myeloid | 1 | 2004 | 76 | 0.27 | Why? |
| Chromosomes, Human, Pair 21 | 3 | 2018 | 90 | 0.27 | Why? |
| Hematologic Neoplasms | 1 | 2017 | 2105 | 0.26 | Why? |
| Genes, MHC Class I | 3 | 2018 | 81 | 0.26 | Why? |
| Receptors, Natural Killer Cell | 3 | 2017 | 14 | 0.25 | Why? |
| Immunity, Innate | 2 | 2020 | 6570 | 0.25 | Why? |
| Immunoglobulin M | 1 | 2020 | 9091 | 0.25 | Why? |
| Inosine | 2 | 2019 | 9 | 0.25 | Why? |
| DNA Methylation | 2 | 2017 | 688 | 0.24 | Why? |
| Bone Marrow | 4 | 2019 | 492 | 0.24 | Why? |
| Transplantation Chimera | 2 | 2018 | 17 | 0.23 | Why? |
| Survival Rate | 9 | 2020 | 9206 | 0.23 | Why? |
| Tumor Suppressor Proteins | 3 | 2018 | 165 | 0.23 | Why? |
| Chromosomes, Human, Pair 8 | 2 | 2018 | 25 | 0.23 | Why? |
| Core Binding Factor Alpha 2 Subunit | 2 | 2018 | 40 | 0.22 | Why? |
| Enzyme-Linked Immunosorbent Assay | 1 | 2017 | 7868 | 0.22 | Why? |
| Perforin | 2 | 2020 | 136 | 0.22 | Why? |
| Adenosine Deaminase | 2 | 2019 | 85 | 0.22 | Why? |
| Polymorphism, Genetic | 2 | 2019 | 1074 | 0.22 | Why? |
| Bone Marrow Transplantation | 2 | 2018 | 343 | 0.22 | Why? |
| CD27 Ligand | 1 | 2020 | 17 | 0.22 | Why? |
| Living Donors | 1 | 2006 | 652 | 0.22 | Why? |
| Cytomegalovirus | 3 | 2018 | 600 | 0.22 | Why? |
| Hematologic Diseases | 2 | 2018 | 614 | 0.22 | Why? |
| Tumor Suppressor Protein p53 | 2 | 2021 | 310 | 0.22 | Why? |
| Stem Cell Transplantation | 1 | 2006 | 531 | 0.21 | Why? |
| Immunosuppressive Agents | 3 | 2019 | 6331 | 0.21 | Why? |
| Epigenomics | 2 | 2018 | 139 | 0.20 | Why? |
| Sirtuin 1 | 1 | 2021 | 100 | 0.20 | Why? |
| Optogenetics | 1 | 2019 | 5 | 0.20 | Why? |
| Receptors, CCR7 | 1 | 2019 | 40 | 0.20 | Why? |
| Forkhead Transcription Factors | 2 | 2018 | 231 | 0.20 | Why? |
| Homeostasis | 2 | 2021 | 582 | 0.20 | Why? |
| HLA-DRB3 Chains | 1 | 2018 | 1 | 0.20 | Why? |
| Cell Proliferation | 8 | 2018 | 1973 | 0.20 | Why? |
| Receptor, Cannabinoid, CB2 | 1 | 2019 | 19 | 0.20 | Why? |
| Cytotoxicity, Immunologic | 3 | 2017 | 287 | 0.20 | Why? |
| Receptors, KIR2DL4 | 1 | 2018 | 1 | 0.19 | Why? |
| Receptors, KIR3DS1 | 1 | 2018 | 2 | 0.19 | Why? |
| Centromere | 1 | 2018 | 12 | 0.19 | Why? |
| Leukemia, Myeloid, Chronic-Phase | 1 | 2018 | 8 | 0.19 | Why? |
| Cyclophosphamide | 2 | 2019 | 387 | 0.19 | Why? |
| T-Box Domain Proteins | 1 | 2018 | 62 | 0.19 | Why? |
| Follow-Up Studies | 11 | 2018 | 17020 | 0.19 | Why? |
| Immunotherapy, Adoptive | 3 | 2018 | 524 | 0.19 | Why? |
| T-Lymphocytes, Cytotoxic | 2 | 2020 | 552 | 0.19 | Why? |
| rhoB GTP-Binding Protein | 1 | 2018 | 2 | 0.19 | Why? |
| Pyrimidines | 2 | 2017 | 1557 | 0.19 | Why? |
| Nanog Homeobox Protein | 1 | 2018 | 11 | 0.19 | Why? |
| Forkhead Box Protein M1 | 1 | 2018 | 4 | 0.19 | Why? |
| Receptors, IgE | 1 | 2018 | 26 | 0.19 | Why? |
| Noonan Syndrome | 1 | 2017 | 3 | 0.19 | Why? |
| Thymoma | 1 | 2019 | 47 | 0.19 | Why? |
| Italy | 13 | 2020 | 38444 | 0.19 | Why? |
| Wiskott-Aldrich Syndrome Protein | 1 | 2018 | 37 | 0.19 | Why? |
| Homeodomain Proteins | 1 | 2019 | 93 | 0.18 | Why? |
| Programmed Cell Death 1 Receptor | 3 | 2019 | 724 | 0.18 | Why? |
| Antigens, CD19 | 1 | 2018 | 98 | 0.18 | Why? |
| Cytomegalovirus Infections | 4 | 2018 | 667 | 0.18 | Why? |
| Thymus Neoplasms | 1 | 2019 | 69 | 0.18 | Why? |
| ras Proteins | 1 | 2018 | 37 | 0.18 | Why? |
| Exons | 1 | 2018 | 158 | 0.18 | Why? |
| Severe Combined Immunodeficiency | 1 | 2019 | 107 | 0.18 | Why? |
| Transplantation, Haploidentical | 1 | 2018 | 53 | 0.18 | Why? |
| Vidarabine | 1 | 2018 | 59 | 0.18 | Why? |
| Osteonecrosis | 1 | 2018 | 55 | 0.18 | Why? |
| Chromosomes, Human, Pair 15 | 1 | 2017 | 13 | 0.18 | Why? |
| Gain of Function Mutation | 1 | 2018 | 54 | 0.18 | Why? |
| Intraepithelial Lymphocytes | 1 | 2018 | 52 | 0.18 | Why? |
| Chromosomes, Human, Pair 17 | 1 | 2017 | 13 | 0.18 | Why? |
| Histocompatibility | 1 | 2018 | 53 | 0.18 | Why? |
| Neurogenesis | 1 | 2018 | 64 | 0.18 | Why? |
| Mucopolysaccharidosis I | 1 | 2017 | 9 | 0.18 | Why? |
| Genetic Heterogeneity | 1 | 2018 | 77 | 0.18 | Why? |
| Imatinib Mesylate | 2 | 2018 | 327 | 0.18 | Why? |
| Receptor, Notch2 | 1 | 2017 | 3 | 0.18 | Why? |
| Class I Phosphatidylinositol 3-Kinases | 1 | 2017 | 43 | 0.18 | Why? |
| Adoptive Transfer | 1 | 2019 | 250 | 0.18 | Why? |
| Brain Stem Neoplasms | 1 | 2017 | 3 | 0.18 | Why? |
| Survival Analysis | 5 | 2018 | 7592 | 0.18 | Why? |
| N-Myc Proto-Oncogene Protein | 1 | 2017 | 6 | 0.18 | Why? |
| Pancreatitis-Associated Proteins | 1 | 2017 | 5 | 0.18 | Why? |
| Mice | 13 | 2019 | 21357 | 0.18 | Why? |
| Receptors, KIR | 1 | 2019 | 167 | 0.17 | Why? |
| src-Family Kinases | 1 | 2017 | 48 | 0.17 | Why? |
| Pons | 1 | 2017 | 25 | 0.17 | Why? |
| Protein Interaction Mapping | 1 | 2020 | 487 | 0.17 | Why? |
| Signaling Lymphocytic Activation Molecule Family | 1 | 2017 | 22 | 0.17 | Why? |
| Focal Adhesion Kinase 1 | 1 | 2017 | 15 | 0.17 | Why? |
| Tetrahydroisoquinolines | 1 | 2017 | 12 | 0.17 | Why? |
| Treatment Outcome | 17 | 2019 | 51732 | 0.17 | Why? |
| Stereotaxic Techniques | 1 | 2017 | 19 | 0.17 | Why? |
| Dioxoles | 1 | 2017 | 19 | 0.17 | Why? |
| Asparaginase | 1 | 2017 | 26 | 0.17 | Why? |
| Aminopeptidases | 1 | 2017 | 41 | 0.17 | Why? |
| Bone Marrow Neoplasms | 1 | 2017 | 60 | 0.17 | Why? |
| Gene Expression Regulation, Developmental | 1 | 2018 | 159 | 0.17 | Why? |
| Enhancer of Zeste Homolog 2 Protein | 1 | 2017 | 40 | 0.17 | Why? |
| Minor Histocompatibility Antigens | 1 | 2017 | 56 | 0.17 | Why? |
| Immune System Diseases | 2 | 2021 | 410 | 0.17 | Why? |
| Leukemia, Myelomonocytic, Chronic | 1 | 2017 | 37 | 0.17 | Why? |
| Oncogene Proteins, Fusion | 1 | 2017 | 52 | 0.17 | Why? |
| Central Nervous System Neoplasms | 1 | 2017 | 88 | 0.16 | Why? |
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2017 | 31 | 0.16 | Why? |
| Neural Stem Cells | 1 | 2018 | 135 | 0.16 | Why? |
| Cerebellum | 1 | 2018 | 119 | 0.16 | Why? |
| Interleukin-1 Receptor-Like 1 Protein | 1 | 2017 | 92 | 0.16 | Why? |
| Cell Movement | 5 | 2018 | 695 | 0.16 | Why? |
| Janus Kinase 3 | 1 | 2016 | 46 | 0.16 | Why? |
| Myeloid-Derived Suppressor Cells | 1 | 2020 | 316 | 0.16 | Why? |
| Cannabinoids | 1 | 2019 | 134 | 0.16 | Why? |
| Osteosarcoma | 1 | 2017 | 83 | 0.16 | Why? |
| Isoantibodies | 1 | 2018 | 134 | 0.16 | Why? |
| Acute Disease | 3 | 2018 | 6029 | 0.16 | Why? |
| Infant, Newborn | 13 | 2020 | 23105 | 0.16 | Why? |
| Carcinogenesis | 1 | 2018 | 236 | 0.16 | Why? |
| SARS Virus | 1 | 2020 | 13021 | 0.16 | Why? |
| Kruppel-Like Transcription Factors | 1 | 2017 | 91 | 0.16 | Why? |
| Antigens, Neoplasm | 1 | 2018 | 230 | 0.16 | Why? |
| Proteasome Inhibitors | 1 | 2017 | 127 | 0.16 | Why? |
| CD4 Antigens | 1 | 2017 | 306 | 0.16 | Why? |
| Transfection | 1 | 2019 | 864 | 0.15 | Why? |
| Immunophenotyping | 3 | 2017 | 1290 | 0.15 | Why? |
| Age Distribution | 3 | 2020 | 3567 | 0.15 | Why? |
| Anemia, Aplastic | 1 | 2017 | 167 | 0.15 | Why? |
| Hemoglobinuria, Paroxysmal | 1 | 2017 | 116 | 0.15 | Why? |
| Gene Frequency | 1 | 2020 | 1210 | 0.15 | Why? |
| Nephrotic Syndrome | 1 | 2017 | 146 | 0.15 | Why? |
| T-Lymphocytes, Regulatory | 2 | 2018 | 698 | 0.15 | Why? |
| Genetic Diseases, X-Linked | 1 | 2017 | 237 | 0.14 | Why? |
| Anemia, Diamond-Blackfan | 1 | 2014 | 3 | 0.14 | Why? |
| Cell Nucleus | 1 | 2017 | 399 | 0.14 | Why? |
| Gene Regulatory Networks | 1 | 2020 | 820 | 0.14 | Why? |
| Gene Expression Regulation, Leukemic | 3 | 2018 | 31 | 0.14 | Why? |
| Antimetabolites, Antineoplastic | 1 | 2015 | 99 | 0.14 | Why? |
| Signal Transduction | 7 | 2020 | 7207 | 0.13 | Why? |
| Salvage Therapy | 1 | 2017 | 417 | 0.13 | Why? |
| Promoter Regions, Genetic | 4 | 2018 | 823 | 0.13 | Why? |
| Lymphocyte Activation | 6 | 2020 | 2742 | 0.13 | Why? |
| RNA Interference | 1 | 2017 | 534 | 0.13 | Why? |
| Bone Neoplasms | 1 | 2017 | 287 | 0.13 | Why? |
| Tumor Escape | 1 | 2013 | 36 | 0.13 | Why? |
| Mice, Knockout | 1 | 2019 | 1815 | 0.13 | Why? |
| Herpesvirus 4, Human | 1 | 2017 | 387 | 0.13 | Why? |
| Virus Activation | 1 | 2018 | 480 | 0.13 | Why? |
| Nuclear Proteins | 1 | 2016 | 321 | 0.13 | Why? |
| Lymphocytes | 3 | 2021 | 3056 | 0.13 | Why? |
| Prednisone | 1 | 2017 | 652 | 0.13 | Why? |
| Myasthenia Gravis | 1 | 2019 | 385 | 0.12 | Why? |
| Neoplastic Stem Cells | 1 | 2014 | 120 | 0.12 | Why? |
| Age of Onset | 3 | 2019 | 557 | 0.12 | Why? |
| Animals | 16 | 2019 | 78931 | 0.12 | Why? |
| Transcription Factors | 1 | 2018 | 784 | 0.12 | Why? |
| Carrier Proteins | 1 | 2016 | 513 | 0.12 | Why? |
| Biopsy | 2 | 2019 | 2811 | 0.12 | Why? |
| Epstein-Barr Virus Infections | 1 | 2017 | 366 | 0.12 | Why? |
| Neoplasm Proteins | 1 | 2018 | 501 | 0.12 | Why? |
| Th1 Cells | 1 | 2018 | 1228 | 0.12 | Why? |
| Neoplasms | 6 | 2021 | 17251 | 0.12 | Why? |
| Nanomedicine | 1 | 2017 | 329 | 0.12 | Why? |
| Flow Cytometry | 3 | 2018 | 2393 | 0.12 | Why? |
| RNA, Long Noncoding | 1 | 2017 | 408 | 0.12 | Why? |
| Polyethylene Glycols | 1 | 2017 | 574 | 0.12 | Why? |
| Transcription, Genetic | 1 | 2018 | 1326 | 0.12 | Why? |
| Down Syndrome | 1 | 2017 | 397 | 0.12 | Why? |
| Cancer Survivors | 1 | 2019 | 588 | 0.11 | Why? |
| Pneumonia, Viral | 7 | 2020 | 243684 | 0.11 | Why? |
| Coronavirus Infections | 7 | 2020 | 253789 | 0.11 | Why? |
| Immunohistochemistry | 1 | 2019 | 2275 | 0.11 | Why? |
| Proteome | 2 | 2021 | 1812 | 0.11 | Why? |
| Exosomes | 1 | 2017 | 567 | 0.11 | Why? |
| Prognosis | 10 | 2020 | 32490 | 0.11 | Why? |
| Antineoplastic Agents, Immunological | 1 | 2018 | 830 | 0.11 | Why? |
| T-Lymphocyte Subsets | 1 | 2018 | 1387 | 0.11 | Why? |
| Pyridines | 1 | 2017 | 680 | 0.11 | Why? |
| Purpura, Thrombocytopenic, Idiopathic | 1 | 2019 | 645 | 0.10 | Why? |
| Apoptosis | 5 | 2019 | 2335 | 0.10 | Why? |
| Young Adult | 11 | 2020 | 93724 | 0.10 | Why? |
| CD8-Positive T-Lymphocytes | 3 | 2019 | 5837 | 0.10 | Why? |
| Daunorubicin | 2 | 2019 | 33 | 0.10 | Why? |
| Eosinophils | 1 | 2015 | 848 | 0.09 | Why? |
| Robotic Surgical Procedures | 1 | 2017 | 787 | 0.09 | Why? |
| Jurkat Cells | 2 | 2019 | 273 | 0.09 | Why? |
| Myeloid Cells | 1 | 2014 | 808 | 0.09 | Why? |
| Adult | 19 | 2021 | 244371 | 0.09 | Why? |
| Immunocompetence | 1 | 2010 | 280 | 0.09 | Why? |
| Mesenchymal Stem Cell Transplantation | 1 | 2020 | 1322 | 0.09 | Why? |
| Genetic Variation | 2 | 2017 | 3919 | 0.09 | Why? |
| Gene Rearrangement | 2 | 2019 | 84 | 0.09 | Why? |
| Disseminated Intravascular Coagulation | 1 | 2017 | 994 | 0.09 | Why? |
| Polymorphism, Single Nucleotide | 2 | 2018 | 3607 | 0.09 | Why? |
| Receptors, Thrombopoietin | 1 | 2007 | 23 | 0.09 | Why? |
| Monocytes | 2 | 2017 | 2978 | 0.09 | Why? |
| Antibodies, Viral | 1 | 2020 | 51949 | 0.09 | Why? |
| Hedgehog Proteins | 2 | 2018 | 39 | 0.09 | Why? |
| Betacoronavirus | 6 | 2020 | 204454 | 0.09 | Why? |
| Coculture Techniques | 2 | 2018 | 258 | 0.08 | Why? |
| Tumor Cells, Cultured | 2 | 2017 | 254 | 0.08 | Why? |
| Nutritional Status | 1 | 2017 | 1403 | 0.08 | Why? |
| Cell Adhesion | 2 | 2018 | 230 | 0.08 | Why? |
| Immunotherapy | 2 | 2017 | 2421 | 0.08 | Why? |
| Cell Cycle Checkpoints | 2 | 2017 | 126 | 0.08 | Why? |
| Drug Delivery Systems | 1 | 2017 | 1365 | 0.08 | Why? |
| Carcinoma, Hepatocellular | 1 | 2017 | 1222 | 0.08 | Why? |
| Ferritins | 1 | 2015 | 2055 | 0.08 | Why? |
| DNA, Viral | 1 | 2017 | 2521 | 0.08 | Why? |
| Pore Forming Cytotoxic Proteins | 1 | 2006 | 45 | 0.08 | Why? |
| fas Receptor | 1 | 2006 | 85 | 0.08 | Why? |
| Blood Platelets | 2 | 2015 | 1704 | 0.08 | Why? |
| Mice, Nude | 2 | 2017 | 340 | 0.08 | Why? |
| Immunity, Cellular | 1 | 2019 | 3614 | 0.08 | Why? |
| Severity of Illness Index | 4 | 2021 | 48226 | 0.08 | Why? |
| Models, Biological | 2 | 2020 | 4907 | 0.07 | Why? |
| Diarrhea | 1 | 2017 | 2743 | 0.07 | Why? |
| Cell Lineage | 2 | 2018 | 241 | 0.07 | Why? |
| Macrophages | 1 | 2017 | 2784 | 0.07 | Why? |
| Megakaryocytes | 1 | 2007 | 274 | 0.07 | Why? |
| HeLa Cells | 2 | 2019 | 1303 | 0.07 | Why? |
| Cytokines | 4 | 2021 | 15010 | 0.07 | Why? |
| Liver Neoplasms | 1 | 2017 | 1666 | 0.07 | Why? |
| Body Mass Index | 1 | 2017 | 4306 | 0.07 | Why? |
| Referral and Consultation | 1 | 2020 | 4816 | 0.07 | Why? |
| Membrane Glycoproteins | 2 | 2020 | 2273 | 0.07 | Why? |
| Retrospective Studies | 11 | 2019 | 105322 | 0.07 | Why? |
| Genotype | 4 | 2019 | 4697 | 0.07 | Why? |
| Leukocyte Count | 3 | 2020 | 3178 | 0.07 | Why? |
| Chronic Disease | 1 | 2018 | 5139 | 0.07 | Why? |
| Time-to-Treatment | 1 | 2020 | 5883 | 0.07 | Why? |
| Inflammation | 3 | 2020 | 13255 | 0.06 | Why? |
| Idarubicin | 2 | 2018 | 15 | 0.06 | Why? |
| Cytarabine | 2 | 2019 | 64 | 0.06 | Why? |
| Kaplan-Meier Estimate | 3 | 2018 | 4260 | 0.06 | Why? |
| Cells, Cultured | 3 | 2019 | 5835 | 0.06 | Why? |
| Diabetes Mellitus, Type 1 | 1 | 2017 | 1969 | 0.06 | Why? |
| Graft Survival | 2 | 2017 | 587 | 0.06 | Why? |
| Polymerase Chain Reaction | 3 | 2018 | 6740 | 0.06 | Why? |
| Mice, Inbred C57BL | 3 | 2018 | 5542 | 0.06 | Why? |
| Bone Marrow Cells | 2 | 2017 | 186 | 0.06 | Why? |
| High-Throughput Nucleotide Sequencing | 3 | 2019 | 3633 | 0.06 | Why? |
| Asymptomatic Infections | 1 | 2021 | 7218 | 0.06 | Why? |
| Antibodies, Monoclonal | 2 | 2019 | 8041 | 0.06 | Why? |
| Glucocorticoids | 1 | 2017 | 4431 | 0.06 | Why? |
| Inflammatory Bowel Diseases | 1 | 2018 | 3209 | 0.05 | Why? |
| Down-Regulation | 2 | 2018 | 1416 | 0.05 | Why? |
| Proportional Hazards Models | 3 | 2020 | 6543 | 0.05 | Why? |
| Nitric Oxide Synthase Type II | 1 | 2020 | 119 | 0.05 | Why? |
| Middle Aged | 13 | 2021 | 270681 | 0.05 | Why? |
| HEK293 Cells | 3 | 2019 | 8394 | 0.05 | Why? |
| Disease Models, Animal | 1 | 2019 | 10998 | 0.05 | Why? |
| Kidney Failure, Chronic | 1 | 2017 | 3222 | 0.05 | Why? |
| Neoplasm Recurrence, Local | 2 | 2018 | 1063 | 0.05 | Why? |
| Myeloid-Lymphoid Leukemia Protein | 1 | 2019 | 6 | 0.05 | Why? |
| Mitoxantrone | 1 | 2019 | 30 | 0.05 | Why? |
| Syndrome | 2 | 2019 | 1310 | 0.05 | Why? |
| Viral Load | 2 | 2020 | 15850 | 0.05 | Why? |
| Antigens, CD | 2 | 2017 | 984 | 0.05 | Why? |
| Prospective Studies | 6 | 2021 | 43301 | 0.05 | Why? |
| K562 Cells | 1 | 2019 | 91 | 0.05 | Why? |
| Disease Management | 1 | 2018 | 6841 | 0.05 | Why? |
| Host-Pathogen Interactions | 1 | 2020 | 11041 | 0.05 | Why? |
| Anti-Inflammatory Agents | 1 | 2019 | 6153 | 0.05 | Why? |
| Immunogenetic Phenomena | 1 | 2019 | 61 | 0.05 | Why? |
| Alu Elements | 1 | 2019 | 22 | 0.05 | Why? |
| HLA-DQ beta-Chains | 1 | 2019 | 33 | 0.05 | Why? |
| E-Box Elements | 1 | 2018 | 1 | 0.05 | Why? |
| Immunocompromised Host | 2 | 2021 | 5150 | 0.05 | Why? |
| Protein Phosphatase 2 | 1 | 2018 | 18 | 0.05 | Why? |
| Neoplasm Staging | 2 | 2018 | 1999 | 0.05 | Why? |
| RNA-Binding Protein FUS | 1 | 2018 | 11 | 0.05 | Why? |
| Chromosomes, Human, Pair 16 | 1 | 2018 | 11 | 0.05 | Why? |
| Forkhead Box Protein O3 | 1 | 2018 | 30 | 0.05 | Why? |
| Germ-Line Mutation | 1 | 2019 | 86 | 0.05 | Why? |
| Transcriptional Regulator ERG | 1 | 2018 | 19 | 0.05 | Why? |
| Risk Factors | 9 | 2018 | 71621 | 0.05 | Why? |
| Erythrocyte Indices | 1 | 2020 | 207 | 0.05 | Why? |
| Gene Duplication | 1 | 2018 | 31 | 0.05 | Why? |
| Mercaptopurine | 1 | 2019 | 68 | 0.05 | Why? |
| Mean Platelet Volume | 1 | 2020 | 203 | 0.05 | Why? |
| Rome | 1 | 2020 | 497 | 0.05 | Why? |
| Histone-Lysine N-Methyltransferase | 1 | 2019 | 82 | 0.05 | Why? |
| Genes, Transgenic, Suicide | 1 | 2018 | 4 | 0.05 | Why? |
| Europe | 3 | 2017 | 12702 | 0.05 | Why? |
| Sequence Analysis, DNA | 2 | 2018 | 2830 | 0.05 | Why? |
| Feedback, Physiological | 1 | 2018 | 56 | 0.05 | Why? |
| Caspase 9 | 1 | 2018 | 38 | 0.05 | Why? |
| Proto-Oncogene Proteins c-cbl | 1 | 2017 | 6 | 0.05 | Why? |
| Adaptor Proteins, Vesicular Transport | 1 | 2019 | 88 | 0.05 | Why? |
| Facility Design and Construction | 1 | 2020 | 189 | 0.05 | Why? |
| Etoposide | 1 | 2019 | 115 | 0.05 | Why? |
| Age Factors | 5 | 2019 | 21039 | 0.05 | Why? |
| Mice, Inbred A | 1 | 2017 | 24 | 0.05 | Why? |
| DNA (Cytosine-5-)-Methyltransferase 1 | 1 | 2017 | 11 | 0.05 | Why? |
| DNA (Cytosine-5-)-Methyltransferases | 1 | 2017 | 20 | 0.05 | Why? |
| Anthracyclines | 1 | 2018 | 65 | 0.05 | Why? |
| Iduronidase | 1 | 2017 | 1 | 0.05 | Why? |
| Granzymes | 1 | 2018 | 197 | 0.04 | Why? |
| Zebrafish | 1 | 2019 | 181 | 0.04 | Why? |
| Programmed Cell Death 1 Ligand 2 Protein | 1 | 2017 | 9 | 0.04 | Why? |
| Transforming Growth Factor beta | 1 | 2020 | 363 | 0.04 | Why? |
| Blast Crisis | 1 | 2018 | 41 | 0.04 | Why? |
| Signaling Lymphocytic Activation Molecule Associated Protein | 1 | 2017 | 4 | 0.04 | Why? |
| E2F2 Transcription Factor | 1 | 2017 | 1 | 0.04 | Why? |
| E2F3 Transcription Factor | 1 | 2017 | 1 | 0.04 | Why? |
| CD48 Antigen | 1 | 2017 | 27 | 0.04 | Why? |
| Retinoblastoma-Binding Protein 2 | 1 | 2017 | 1 | 0.04 | Why? |
| Tissue Array Analysis | 1 | 2017 | 75 | 0.04 | Why? |
| G2 Phase Cell Cycle Checkpoints | 1 | 2017 | 25 | 0.04 | Why? |
| RNA, Neoplasm | 1 | 2017 | 34 | 0.04 | Why? |
| Phenotype | 2 | 2019 | 4037 | 0.04 | Why? |
| Cranial Irradiation | 1 | 2017 | 20 | 0.04 | Why? |
| Cytoskeleton | 1 | 2018 | 99 | 0.04 | Why? |
| Azepines | 1 | 2017 | 17 | 0.04 | Why? |
| Tumor Stem Cell Assay | 1 | 2017 | 12 | 0.04 | Why? |
| Neoplasm Transplantation | 1 | 2017 | 55 | 0.04 | Why? |
| Mucositis | 1 | 2017 | 40 | 0.04 | Why? |
| Spheroids, Cellular | 1 | 2018 | 124 | 0.04 | Why? |
| Transcriptional Activation | 1 | 2018 | 196 | 0.04 | Why? |
| Potassium Channels, Inwardly Rectifying | 1 | 2017 | 29 | 0.04 | Why? |
| Thiazolidinediones | 1 | 2017 | 70 | 0.04 | Why? |
| Acyltransferases | 1 | 2017 | 61 | 0.04 | Why? |
| Receptors, CCR1 | 1 | 2017 | 49 | 0.04 | Why? |
| Liquid Biopsy | 1 | 2018 | 114 | 0.04 | Why? |
| Xenograft Model Antitumor Assays | 1 | 2018 | 274 | 0.04 | Why? |
| Codon | 1 | 2018 | 287 | 0.04 | Why? |
| Podocytes | 1 | 2017 | 82 | 0.04 | Why? |
| HLA-A2 Antigen | 1 | 2018 | 134 | 0.04 | Why? |
| Receptors, CXCR4 | 1 | 2017 | 83 | 0.04 | Why? |
| Antigens, CD34 | 1 | 2017 | 125 | 0.04 | Why? |
| Chromatin | 1 | 2017 | 107 | 0.04 | Why? |
| Gene Expression | 2 | 2018 | 3332 | 0.04 | Why? |
| Transplant Recipients | 3 | 2018 | 4982 | 0.04 | Why? |
| Aged | 8 | 2021 | 215776 | 0.04 | Why? |
| Osteoblasts | 1 | 2017 | 87 | 0.04 | Why? |
| Isoquinolines | 1 | 2017 | 69 | 0.04 | Why? |
| Animals, Newborn | 1 | 2018 | 350 | 0.04 | Why? |
| Receptors, CXCR3 | 1 | 2017 | 159 | 0.04 | Why? |
| Conservative Treatment | 1 | 2020 | 349 | 0.04 | Why? |
| Drug Screening Assays, Antitumor | 1 | 2017 | 138 | 0.04 | Why? |
| Sex Factors | 3 | 2019 | 11014 | 0.04 | Why? |
| Quinoxalines | 1 | 2017 | 95 | 0.04 | Why? |
| Risk Assessment | 2 | 2018 | 25439 | 0.04 | Why? |
| International Agencies | 1 | 2018 | 202 | 0.04 | Why? |
| Kidney Transplantation | 1 | 2017 | 5397 | 0.04 | Why? |
| Neoplasms, Second Primary | 1 | 2017 | 100 | 0.04 | Why? |
| Astrocytes | 1 | 2019 | 298 | 0.04 | Why? |
| Lymphocytes, Tumor-Infiltrating | 1 | 2017 | 130 | 0.04 | Why? |
| Adipocytes | 1 | 2017 | 173 | 0.04 | Why? |
| Gene Deletion | 1 | 2018 | 430 | 0.04 | Why? |
| Pandemics | 9 | 2020 | 389249 | 0.04 | Why? |
| Quinazolinones | 1 | 2017 | 135 | 0.04 | Why? |
| Primary Cell Culture | 1 | 2018 | 501 | 0.04 | Why? |
| Body Fluids | 1 | 2020 | 451 | 0.04 | Why? |
| CpG Islands | 1 | 2017 | 230 | 0.04 | Why? |
| Siblings | 1 | 2017 | 226 | 0.04 | Why? |
| Gene Knockdown Techniques | 1 | 2017 | 347 | 0.04 | Why? |
| Aminopyridines | 1 | 2017 | 121 | 0.04 | Why? |
| Enzyme Activation | 1 | 2017 | 425 | 0.04 | Why? |
| Extracellular Matrix | 1 | 2017 | 189 | 0.04 | Why? |
| Antibody-Dependent Cell Cytotoxicity | 1 | 2018 | 349 | 0.04 | Why? |
| 3' Untranslated Regions | 1 | 2017 | 318 | 0.04 | Why? |
| Viral Regulatory and Accessory Proteins | 1 | 2021 | 482 | 0.04 | Why? |
| Cytogenetic Analysis | 1 | 2015 | 21 | 0.04 | Why? |
| Heterografts | 1 | 2016 | 203 | 0.04 | Why? |
| Hep G2 Cells | 1 | 2017 | 391 | 0.04 | Why? |
| Interleukin-2 Receptor alpha Subunit | 1 | 2017 | 234 | 0.04 | Why? |
| Receptors, Tumor Necrosis Factor, Type I | 1 | 2017 | 229 | 0.04 | Why? |
| Cohort Studies | 4 | 2020 | 36005 | 0.04 | Why? |
| Plasmids | 1 | 2019 | 840 | 0.04 | Why? |
| Time Factors | 5 | 2018 | 31397 | 0.04 | Why? |
| Tumor Microenvironment | 1 | 2017 | 264 | 0.04 | Why? |
| Exome | 1 | 2017 | 207 | 0.04 | Why? |
| Neoplasm Invasiveness | 1 | 2018 | 582 | 0.04 | Why? |
| Genetic Testing | 1 | 2019 | 395 | 0.04 | Why? |
| Gene Expression Profiling | 2 | 2017 | 3788 | 0.04 | Why? |
| Image-Guided Biopsy | 1 | 2017 | 185 | 0.04 | Why? |
| Blotting, Western | 1 | 2017 | 863 | 0.04 | Why? |
| Triazines | 1 | 2017 | 246 | 0.04 | Why? |
| Interleukin-1beta | 1 | 2020 | 992 | 0.04 | Why? |
| DNA Mutational Analysis | 1 | 2017 | 581 | 0.04 | Why? |
| Multivariate Analysis | 2 | 2017 | 5440 | 0.04 | Why? |
| CD4-Positive T-Lymphocytes | 1 | 2010 | 4545 | 0.04 | Why? |
| Blood Cell Count | 1 | 2020 | 1101 | 0.04 | Why? |
| Proto-Oncogene Proteins c-akt | 1 | 2017 | 372 | 0.04 | Why? |
| Fluorescent Antibody Technique | 1 | 2017 | 835 | 0.04 | Why? |
| DNA-Binding Proteins | 1 | 2018 | 469 | 0.04 | Why? |
| Toll-Like Receptor 3 | 1 | 2017 | 391 | 0.03 | Why? |
| Heterocyclic Compounds, 3-Ring | 1 | 2017 | 275 | 0.03 | Why? |
| Longitudinal Studies | 2 | 2020 | 9893 | 0.03 | Why? |
| Patient Outcome Assessment | 1 | 2018 | 707 | 0.03 | Why? |
| Histones | 1 | 2017 | 371 | 0.03 | Why? |
| Immunoassay | 1 | 2010 | 4485 | 0.03 | Why? |
| Drug Resistance, Neoplasm | 1 | 2018 | 447 | 0.03 | Why? |
| Toll-Like Receptor 4 | 1 | 2017 | 390 | 0.03 | Why? |
| Neonatal Screening | 1 | 2017 | 285 | 0.03 | Why? |
| Protein Processing, Post-Translational | 1 | 2017 | 634 | 0.03 | Why? |
| Neutrophils | 2 | 2020 | 5476 | 0.03 | Why? |
| Coronaviridae | 1 | 2020 | 923 | 0.03 | Why? |
| Adenosine | 1 | 2018 | 509 | 0.03 | Why? |
| Thrombocytopenia | 1 | 2007 | 2093 | 0.03 | Why? |
| Morbidity | 1 | 2020 | 1426 | 0.03 | Why? |
| Disease Progression | 3 | 2017 | 13580 | 0.03 | Why? |
| Protein Interaction Maps | 1 | 2021 | 1333 | 0.03 | Why? |
| Demography | 1 | 2020 | 1660 | 0.03 | Why? |
| Clinical Laboratory Techniques | 1 | 2020 | 23402 | 0.03 | Why? |
| Major Histocompatibility Complex | 1 | 2013 | 70 | 0.03 | Why? |
| Rare Diseases | 1 | 2017 | 373 | 0.03 | Why? |
| Area Under Curve | 1 | 2020 | 2564 | 0.03 | Why? |
| Immunoglobulin G | 1 | 2017 | 21571 | 0.03 | Why? |
| Receptors, Immunologic | 1 | 2017 | 555 | 0.03 | Why? |
| Drug Eruptions | 1 | 2017 | 319 | 0.03 | Why? |
| Pharynx | 1 | 2020 | 1544 | 0.03 | Why? |
| Sensitivity and Specificity | 4 | 2020 | 22971 | 0.03 | Why? |
| Chemical and Drug Induced Liver Injury | 1 | 2017 | 451 | 0.03 | Why? |
| Triazoles | 1 | 2017 | 440 | 0.03 | Why? |
| Cause of Death | 2 | 2019 | 4823 | 0.03 | Why? |
| Autoimmune Diseases | 1 | 2006 | 1996 | 0.03 | Why? |
| RNA, Small Interfering | 1 | 2017 | 817 | 0.03 | Why? |
| Sequence Alignment | 1 | 2018 | 2109 | 0.03 | Why? |
| Receptors, Antigen, T-Cell | 1 | 2018 | 760 | 0.03 | Why? |
| Multiple Sclerosis | 2 | 2018 | 2600 | 0.03 | Why? |
| Interleukins | 1 | 2017 | 762 | 0.03 | Why? |
| Mitochondria | 1 | 2019 | 857 | 0.03 | Why? |
| Interleukin-10 | 1 | 2018 | 1409 | 0.03 | Why? |
| Imaging, Three-Dimensional | 1 | 2017 | 680 | 0.03 | Why? |
| Purines | 1 | 2017 | 816 | 0.03 | Why? |
| Autoimmunity | 1 | 2019 | 841 | 0.03 | Why? |
| Stem Cells | 1 | 2017 | 595 | 0.03 | Why? |
| Protein Binding | 2 | 2018 | 11430 | 0.03 | Why? |
| Brain | 2 | 2019 | 5133 | 0.03 | Why? |
| Epigenesis, Genetic | 1 | 2017 | 711 | 0.03 | Why? |
| Fatal Outcome | 1 | 2020 | 3438 | 0.03 | Why? |
| Fanconi Anemia | 1 | 2010 | 15 | 0.03 | Why? |
| Base Sequence | 1 | 2018 | 3581 | 0.03 | Why? |
| RNA-Binding Proteins | 1 | 2018 | 1022 | 0.03 | Why? |
| Computed Tomography Angiography | 1 | 2020 | 2153 | 0.03 | Why? |
| Proteomics | 1 | 2021 | 2481 | 0.03 | Why? |
| Clinical Protocols | 1 | 2021 | 2734 | 0.03 | Why? |
| Aged, 80 and over | 1 | 2020 | 88759 | 0.03 | Why? |
| Up-Regulation | 1 | 2017 | 2249 | 0.02 | Why? |
| Amino Acid Substitution | 2 | 2007 | 1706 | 0.02 | Why? |
| Platelet Count | 1 | 2015 | 1381 | 0.02 | Why? |
| RNA | 1 | 2017 | 1278 | 0.02 | Why? |
| Combined Modality Therapy | 1 | 2018 | 3395 | 0.02 | Why? |
| Diagnostic Tests, Routine | 1 | 2020 | 2643 | 0.02 | Why? |
| Abnormalities, Multiple | 1 | 2008 | 75 | 0.02 | Why? |
| Chimerism | 1 | 2007 | 10 | 0.02 | Why? |
| DNA Repair | 1 | 2008 | 114 | 0.02 | Why? |
| Protein Kinase Inhibitors | 1 | 2018 | 1585 | 0.02 | Why? |
| Survivors | 1 | 2020 | 2619 | 0.02 | Why? |
| Leukocytes, Mononuclear | 1 | 2018 | 2115 | 0.02 | Why? |
| Peptides | 1 | 2020 | 2513 | 0.02 | Why? |
| ROC Curve | 1 | 2020 | 6024 | 0.02 | Why? |
| Ligands | 1 | 2013 | 1300 | 0.02 | Why? |
| Thrombopoietin | 1 | 2007 | 52 | 0.02 | Why? |
| Viral Envelope Proteins | 1 | 2020 | 3539 | 0.02 | Why? |
| Molecular Targeted Therapy | 1 | 2017 | 1579 | 0.02 | Why? |
| Autoantibodies | 1 | 2019 | 2094 | 0.02 | Why? |
| Clinical Trials as Topic | 2 | 2020 | 7330 | 0.02 | Why? |
| Congenital Abnormalities | 1 | 2008 | 170 | 0.02 | Why? |
| Patient Selection | 1 | 2021 | 4560 | 0.02 | Why? |
| Patient Isolation | 1 | 2020 | 3182 | 0.02 | Why? |
| Incidence | 2 | 2019 | 25622 | 0.02 | Why? |
| Oxygen Inhalation Therapy | 1 | 2020 | 3629 | 0.02 | Why? |
| Registries | 2 | 2019 | 12327 | 0.02 | Why? |
| Gene Expression Regulation | 1 | 2018 | 4020 | 0.02 | Why? |
| Pilot Projects | 1 | 2017 | 5182 | 0.02 | Why? |
| Dose-Response Relationship, Drug | 1 | 2015 | 3776 | 0.02 | Why? |
| Biomarkers | 2 | 2020 | 23361 | 0.02 | Why? |
| Risk | 1 | 2018 | 5288 | 0.02 | Why? |
| Consensus | 1 | 2020 | 6345 | 0.02 | Why? |
| Transcriptome | 1 | 2018 | 3466 | 0.02 | Why? |
| Respiration, Artificial | 2 | 2020 | 22116 | 0.02 | Why? |
| Genomics | 1 | 2017 | 3118 | 0.02 | Why? |
| Binding Sites | 1 | 2017 | 6201 | 0.02 | Why? |
| Renin-Angiotensin System | 1 | 2020 | 3661 | 0.02 | Why? |
| Sequence Homology, Amino Acid | 1 | 2007 | 945 | 0.02 | Why? |
| Molecular Diagnostic Techniques | 1 | 2020 | 4239 | 0.02 | Why? |
| Fibrin Fibrinogen Degradation Products | 1 | 2020 | 5993 | 0.02 | Why? |
| RNA, Messenger | 1 | 2017 | 5131 | 0.02 | Why? |
| Specimen Handling | 1 | 2020 | 6190 | 0.02 | Why? |
| Nervous System Diseases | 1 | 2021 | 4092 | 0.02 | Why? |
| Viral Proteins | 1 | 2021 | 7370 | 0.02 | Why? |
| Interleukin-6 | 1 | 2020 | 7522 | 0.01 | Why? |
| Molecular Sequence Data | 1 | 2007 | 3198 | 0.01 | Why? |
| Dendritic Cells | 1 | 2010 | 1330 | 0.01 | Why? |
| Lung | 2 | 2020 | 31049 | 0.01 | Why? |
| RNA, Viral | 2 | 2020 | 32276 | 0.01 | Why? |
| Immunologic Factors | 1 | 2017 | 4206 | 0.01 | Why? |
| Databases, Factual | 1 | 2015 | 6248 | 0.01 | Why? |
| Predictive Value of Tests | 1 | 2015 | 9537 | 0.01 | Why? |
| Case-Control Studies | 1 | 2019 | 17671 | 0.01 | Why? |
| Algorithms | 1 | 2017 | 7346 | 0.01 | Why? |
| Postoperative Complications | 1 | 2017 | 5861 | 0.01 | Why? |
| Real-Time Polymerase Chain Reaction | 1 | 2017 | 11367 | 0.01 | Why? |
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2017 | 13720 | 0.01 | Why? |
| Prevalence | 1 | 2019 | 25773 | 0.01 | Why? |
| Lymphopenia | 1 | 2008 | 2669 | 0.01 | Why? |
| Obesity | 1 | 2017 | 7388 | 0.01 | Why? |
| Amino Acid Sequence | 1 | 2007 | 6049 | 0.01 | Why? |
| Organ Transplantation | 1 | 2010 | 2616 | 0.01 | Why? |
| Lymphocyte Count | 1 | 2006 | 4758 | 0.01 | Why? |
| Intensive Care Units | 1 | 2020 | 29594 | 0.01 | Why? |
| Reproducibility of Results | 1 | 2010 | 11304 | 0.01 | Why? |
| Antiviral Agents | 1 | 2020 | 41703 | 0.01 | Why? |